Filamon Limited

Developing breakthrough drugs urgently needed for an increasingly ageing society

Learn more

Welcome to Filamon

An Australian clinical-stage company focused on the bourgeoning market for the unmet needs of degenerative and inflammatory diseases that come with increasing age and which diminish our ability to live long, productive and healthy lives.

Diseases that account for the majority of hospital admissions, >50% of all deaths, and a rapidly growing impost on national health budgets.

Diseases that to date remain inadequately treated or, in many cases, totally untreated, because we lack the drugs able to correct the known faults.

What we do?

Making previously 'undruggable' targets 'druggable'

In an important breakthrough, Filamon has found a way of drugging the 'undruggable' targets in a way that does not leave the patient exposed to unacceptable toxicity.

This breakthrough now clears the way to providing more effective treatments for some of society's most debilitating and lethal health problems.

Learn more

Who are we?

Filamon is a public clinical-stage drug discovery and drug development company.

Filamon has partnerships with eminent research institutions in both Australia and the USA:

  • Henry Ford Health, a premier academic medical centre based in Detroit, Michigan
  • Western Sydney University
  • Ingham Institute for Applied Medical Research

Our focus is a family of first-in-class drugs that offer breakthrough treatments of chronic degenerative and inflammatory diseases primarily, but not exclusively, associated with ageing.

Learn more

Our Research

Filamon currently has three platform technologies, all linked by the ability to correct malfunctioning major genes involved in chronic inflammatory diseases embracing cancer, autoimmune diseases and neurodegenerative diseases. In particular, doing so in a well-tolerated way that previously has been considered in medical research to be unachievable.

Learn more

Our Pipeline

The Filamon Pipeline is built around three master switches known to be major players in the areas of cancer, cardiovascular disease, vision loss, neurodegenerative diseases (such as Alzheimer's and Parkinson's disease) and psychiatric illnesses.

Learn more